Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bermekimab in Adults With Moderate-to-Severe Atopic Dermatitis (Phase 2a)
2020-005900-21Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Bermekimab IV with Placebo IV (2 arms). Primary endpoint: Proportion of participants with EASI-75. Started Jul 2021; status: terminated.
02
Drugs
bermekimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2020-005900-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005900-21.